[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].
OBJECTIVE
To observe the effects of Tanshinone II A (Tan II A) on acute promyelocytic leukemia (APL) characterized by resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).


METHODS
A 21-year-old male patient with relapsed APL, who previously received the maintenance therapy with ATRA,ATO, 6-Mercaptopurine (6-MP) and Methotrexate (MTX) for 1 year, was given Tan II A 80 mg intravenously once a day, and the changes of hematological parameters and side effects of Tan II A were observed.


RESULTS
The patient reached morphologically complete remission after using Tan II A intravenously for 54 days. During Tan II A treatment, obvious side effect was not observed.


CONCLUSIONS
Tan II A treatment may be effective in relapsed APL cases with ATRA and ATO resistance.
Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
Lei
L
Yang
Yu-ping
YP
Gong
Yi-ming
YM
Yang
Shu
S
Luo
D045784:Abietanes / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
D045784:Abietanes; D000972:Antineoplastic Agents, Phytogenic; D001152:Arsenicals; D010087:Oxides; C021751:tanshinone; D014212:Tretinoin; D015122:Mercaptopurine; D000077237:Arsenic Trioxide; D008727:Methotrexate